Ambroxol dosage and evidence
Written by Aaron CuhaReviewed Sep 2026
The short answer
Ambroxol is a cough medicine sold over the counter in much of the world. At high doses it raises a key enzyme in the brain. The one proper test in Parkinson's disease dementia gave 55 people the drug or a dummy pill for 52 weeks. The enzyme went up. But people on the dummy pill did just as well on both main measures.
Evidence grade for Ambroxol: Limited. The rule: people have taken it in a published study, but fewer than 100 of them. The sum on this page: 2 completed trials, 73 people given it. A grade counts how much has been done to people, not whether it works.
- People given it
- 73
- Human studies
- 2
- Found nothing
- 0
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
2 completed trials, 73 people given it
1 effects reported, 1 unwanted, by people using it, not a trial
Goal pages: Brain, memory and mood
In plain English
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Ambroxol is a cough medicine sold over the counter in much of the world. It is not approved in the US. At very high doses, it raises an enzyme in the brain linked to Parkinson's. That is why it gets talked about for brain health.
What people take it for
- Slowing Parkinson's disease.
- Protecting the brain with age.
- Loosening mucus in a cough, which is its normal use.
What studies in people showed
Two studies in people with Parkinson's. The bigger one gave 55 people with Parkinson's dementia the drug or a dummy pill for a year. The drug hit its target in the brain. But people on the dummy pill did just as well on thinking tests and on everything else. The smaller one had 23 people and no comparison group. The drug reached the brain and raised the enzyme 35 percent. But the enzyme's activity fell 19 percent, and the clumping protein rose 13 percent. That is the opposite of what was hoped. No study has looked at ageing.
What people report
Reports, not study results
The good
- We have not collected user reports on this one yet.
The bad
- In the year-long study, stomach side effects were more common on ambroxol than on the dummy pill.
Where these come from: We have no user reports. The side effect line comes from the year-long study on this page.
My bottom line
It hits its target, and it did not help the patients. If you have Parkinson's, ask your brain doctor about the studies now signing people up. Do not dose a cough medicine at twenty times the label.
An opinion, not a finding. I am a coach, not a doctor.
What it has been measured to do
Measured in people
Goals Ambroxol has been tested for in people, biggest studies first. We count only what the studies on this page say, so the real numbers may be higher.
- Memory and thinking55 people · 1 study
35 of the 36 indexed goals have no study of any kind behind Ambroxol
No study in people, animals or cells on this page reports a result for these. That does not prove Ambroxol does nothing for them. It does mean anything you have heard about Ambroxol and one of these did not come from a study cited here.
Show full evidence
What is Ambroxol?
Ambroxol is a cough medicine sold over the counter in much of the world. At high doses it raises a key enzyme in the brain. The one proper test in Parkinson's disease dementia gave 55 people the drug or a dummy pill for 52 weeks. The enzyme went up. But people on the dummy pill did just as well on both main measures.
Ambroxol has been sold for decades to loosen mucus in a cough. Its second life began in 2009. A lab search found it helps an enzyme called glucocerebrosidase fold the right way and reach the cell's recycling centre. That enzyme matters in Gaucher disease, a rare inherited illness.
It matters for Parkinson's too. Changes in the gene for that enzyme, GBA1, are the biggest single genetic risk for Parkinson's disease. Low enzyme activity goes along with a build-up of alpha-synuclein, the protein that clumps in Parkinson's. So raising the enzyme makes sense on paper. It has now been tested twice in patients.
The 2025 study was the real test. 55 people with Parkinson's disease dementia got ambroxol or a dummy pill for 52 weeks. Nobody knew who got what. The main measures were a thinking test and a doctor's overall rating of change. The drug hit its target again, with higher enzyme levels at week 26. But the groups did not differ on the main measures or on anything else.
The earlier 2020 study had no comparison group. 23 people started and 18 finished. Doses rose up to 1.26 g a day. It answered what it asked. The drug reached the fluid around the brain. The enzyme protein there rose 35 percent. People could handle the drug. It also found two things that muddy the story. The enzyme's actual activity fell 19 percent instead of rising. And alpha-synuclein rose 13 percent, the opposite of what was hoped.
How does Ambroxol work?
Ambroxol acts like a helper for the enzyme glucocerebrosidase. It grabs the enzyme as it is being built, helps it hold its shape, and lets go once it reaches the cell's recycling centre. More working enzyme there should help the cell break down alpha-synuclein, the protein that clumps in Parkinson's. That is the idea. Its cough action, thinning mucus, has nothing to do with this and happens at about a twentieth of the dose. Ambroxol also numbs nerves a little, which is why the low-dose lozenge eases a sore throat.
What have studies in people found about Ambroxol?
Two studies in Parkinson's disease, with 55 and 23 people. Both showed the drug reaches the brain and raises the enzyme. Neither showed patients got better. The one with a dummy pill group found no difference on either main measure.
- 2025, Parkinson's disease dementia, 55 people over 52 weeks, with a dummy pill group: people on the high dose did no better than people on the dummy pill. That held for the thinking test, the doctor's overall rating, and every other measure.
- 2020, 18 people finished, no comparison group: the drug showed up in the fluid around the brain. Enzyme protein rose 35 percent, enzyme activity fell 19 percent, and alpha-synuclein rose 13 percent.
- Both studies showed the drug hits its target. That means the biology works. It does not show that patients benefit.
- Decades of over-the-counter cough use, at about a twentieth of the study dose, give a safety background. They say nothing about whether it helps the brain.
- No study of ambroxol has measured lifespan, frailty or any general sign of ageing in anyone.
What this does not tell you: Both studies were small, and each ran at one centre. In the 2025 study, the high-dose group had only 22 people who could be assessed. That is too few to rule out a small effect. A no-difference result in people who already have dementia also cannot rule out a benefit if started earlier. Larger studies now running are testing that. What it does rule out is anyone saying ambroxol has been shown to slow Parkinson's. The one proper test that looked did not find it.
The state of the research
Any old drug used for something new raises two separate questions, and they have different answers. First: does the drug do what it was approved to do? Here, big studies in sick people settle that. Second: does it slow ageing in people? No study has tested that. A strong answer to the first question says nothing about the second. Treating the approved use as part proof that it slows ageing is the biggest mistake in this field.
Ambroxol shows why hitting the target is not the same as helping the patient. Both studies proved the drug gets into the brain and moves the enzyme. That is a real result. The 2025 study then asked whether that helped thinking. It found nothing on either main measure, or on anything else. Reporting the first half and leaving out the second is how a failed study gets called promising.
The 2020 study also had two results that go against the idea, and they rarely get quoted. Enzyme activity in the brain fluid fell 19 percent while the enzyme protein rose 35 percent. And alpha-synuclein rose 13 percent, when the theory says it should fall. The authors report both plainly. News stories tend to keep the 35 percent and drop the rest.
Several bigger studies are running. One is a large final-stage study in the United Kingdom. Others are in people with GBA1-linked Parkinson's, and in Lewy body dementia. Until one of those reports, the honest statement is this. Ambroxol reaches its target in the human brain. It has not been shown to change the course of any disease.
The evidence, in charts
Fig. 1a · how many people
73people, across 2 studies in people cited here
| Study | People | Share |
|---|---|---|
| JAMA Neurology 2025 | 55 | 75% |
| JAMA Neurology 2020 | 18 | 25% |
One study holds 75% of these people, so the total rests more on one study than its size suggests. Counts are the number of people each study on this page says it signed up. That includes studies that only watched people and gave nobody the compound. 1 more study in people gives no headcount and is not counted here. Studies still signing people up are left out, and only studies cited on this page are counted.
Fig. 1b · evidence mix
3 of 5 sources here are studies in people. The rest are not.
- Study in people · done in people360%
- Lab (cells in a dish) · cells or tissue120%
- Review of studies · sums up other studies120%
Counted from the list of sources on this page. It counts only what we cite, so there may be more studies out there. A review counts once, however many studies it sums up.
Fig. 2 · evidence over time
The studies cover 4 different years, 2009 to 2025, counted from the list of sources on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Not approved
CA
Not approved
Approved in 1 of 4, by prescription in 0, not approved in 3. This is what the law says, not a verdict on the science. See Legal status below for the full text and any notes.
Fig. 4 · how much does what
Nobody has tested different amounts in people
This chart would show how the effect changes as the amount goes up. For this compound, nobody has measured that in people. So we leave it empty. We will not borrow an animal chart and pretend it works the same in people.
Fig. 5 · what the molecule is
- Kind of compound
- Small molecule
- Molecule weight
- 378.1 Da as the free base; 414.6 Da as the hydrochloride
- Half-life
- About 10 hoursMedium, 6 to 24 hours
- Chain length
- None on file
No amino acid sequence is on file for Ambroxol, which is expected: a small molecule is not built from amino acids.
The studies we cite
- Study in people2020Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial
The drug reached the brain and moved its target, in a study with nothing to compare against. 23 people with moderate Parkinson disease started and 18 finished, taking rising oral doses of ambroxol up to 1.26 g a day for 186 days. Everybody knew what they were getting. In the fluid around the brain the target protein rose 35 percent, enzyme activity fell 19 percent, and alpha-synuclein rose 13 percent. Movement scores improved 6.8 points. Here is the problem. With no comparison group, improvement in a fluctuating condition means nothing.
AiM-PD. Single centre, open label, no control group. 23 patients with moderate Parkinson disease entered and 18 completed, on escalating oral ambroxol to 1.26 g per day for 186 days. Ambroxol reached the cerebrospinal fluid and cerebrospinal fluid glucocerebrosidase protein rose 35 percent. Cerebrospinal fluid glucocerebrosidase enzyme activity decreased by 19 percent and cerebrospinal fluid alpha-synuclein rose 13 percent. Motor scores improved by 6.8 points on MDS-UPDRS part 3, which in an uncontrolled study of a symptomatic disease is not interpretable as efficacy, and the authors call for placebo-controlled trials.
- Study in people2025Ambroxol as a Treatment for Parkinson Disease Dementia: A Randomized Clinical Trial
The proper trial was finally run, and it came back empty. 55 people with Parkinson disease dementia were assigned by chance to 525 mg of ambroxol a day, 1,050 mg, or a dummy, for a year. Nobody knew which. Comparing the high dose against the dummy, nothing separated the groups on thinking scores or on anything else. The drug did hit its target, running the enzyme higher at week 26. So the biology worked and the patients did not benefit. Stomach side effects were more common on ambroxol.
The controlled test, and it is null. 52 week phase 2 double-blind placebo-controlled trial, single centre, 75 screened and 55 randomised to ambroxol 525 mg a day, 1,050 mg a day or placebo. Comparing high dose with placebo, there was no evidence of differences between groups on primary or secondary outcomes, the primaries being ADAS-Cog-13 and Clinician's Global Impression of Change. Target engagement was confirmed, with glucocerebrosidase higher at week 26 on drug than placebo. Gastrointestinal adverse events were more frequent on ambroxol, 12 percent of events against 5 percent.
- Study in people2018Ambroxol in Disease Modification in Parkinson Disease
This is the registry entry for that uncontrolled study, not a separate result. It is listed as completed, with 23 people actually enrolled, running from December 2016 to May 2018. The record matches what the published paper describes: a small study with no group to compare against. There is nothing extra here to report.
The AiM-PD registration. Listed as completed, actual enrolment 23, ran from December 2016 to May 2018. The registry record confirms the small, uncontrolled design that the publication describes.
- Review of studies2020Precision Medicine for Parkinson's Disease: Ambroxol for Glucocerebrosidase-Associated Parkinson's Disease, First Trial Completed
An expert comment on the 2020 Parkinson's study. It calls that study a first test of whether the drug hits its target in people. It does not treat it as proof that patients got better.
A commentary on AiM-PD from the movement disorders field, framing it as a first-in-class target engagement study rather than as evidence of clinical benefit.
- Lab (cells in a dish)2009Identification and characterization of ambroxol as an enzyme enhancement agent for Gaucher disease
In a dish. This lab screen of approved drugs found that ambroxol helps the enzyme linked to Gaucher disease work better. Everything later in Parkinson's grows out of this cell result.
The origin of the repurposing idea. A screen of approved drugs identified ambroxol as a pharmacological chaperone that enhances glucocerebrosidase in Gaucher disease. Everything downstream in Parkinson disease follows from this cell biology result.
Common questions
Has Ambroxol been tested in people?
Yes. 73 people given it across 2 completed trials cited here, 0 of which found nothing. Ambroxol is a cough medicine sold over the counter in much of the world. At high doses it raises a key enzyme in the brain. The one proper test in Parkinson's disease dementia gave 55 people the drug or a dummy pill for 52 weeks. The enzyme went up. But people on the dummy pill did just as well on both main measures.
What is the Ambroxol dosage?
No human dose established. Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose. 2 completed trials, 73 people given it
Is Ambroxol FDA-approved?
Not approved in the United States for any use. Widely sold over the counter in Europe, Asia and Latin America to loosen mucus. The Parkinson disease work is investigational everywhere, and it uses doses far above the ones used for mucus.
Did the ambroxol Parkinson's trials work?
They showed the drug does what it should inside the body. They did not show it treats the disease. Both studies found ambroxol reaches the fluid around the brain and raises the enzyme. The only study with a dummy pill group followed 55 people with Parkinson's disease dementia for 52 weeks. People on the dummy pill did just as well on both main thinking measures and on everything else.
What about the motor improvement in the first trial?
The first study reported a 6.8 point gain on a movement score. That study had no comparison group, and everyone knew they were on the drug. In Parkinson's, movement scores can improve from hope and practice alone. So that number cannot be credited to the drug. The authors themselves asked for a study with a dummy pill group. When that was run, it found no difference.
Is the cough medicine dose the same as the trial dose?
No, and the gap is big. The throat lozenge sold in the UK is 20 mg. The Parkinson's studies used 525 to 1,260 mg a day by mouth, with doctors watching. Taking cough medicine packets to reach that dose means taking an amount only ever given inside a research study.
Does ambroxol slow ageing?
No study has asked. All the human work is in Parkinson's and Gaucher disease. None of it measured lifespan, frailty or any general ageing outcome. People in longevity circles talk about it because of the cell recycling idea. An idea is not a finding.
Should someone with a GBA1 variant take it?
That is a question for a brain doctor. The honest input is that the proper studies do not support it yet. Studies in people with GBA1-linked Parkinson's are signing people up now. That is the right route, not taking a cough medicine at twenty times the label dose on your own.